ClinVar

Description

The CHEK2 p.Gly306Ala variant was identified in 11 of 114364 proband chromosomes (frequency: 0.00009) from individuals or families with breast cancer and was not identified in 2218 control chromosomes from healthy individuals (Le Calvez-Kelm 2011, Leedom 2016, Susswein 2016). The variant was also identified in dbSNP (ID: rs587780192) as "With Likely pathogenic allele ", and in ClinVar (classified as likely pathogenic by GeneDx, Ambry Genetics and two other submitters; as uncertain significance by Invitae and one clinical laboratory). The variant was identified in control databases in 12 of 276948 chromosomes at a frequency of 0.00004 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Other in 1 of 6460 chromosomes (freq: 0.0002), European in 8 of 126606 chromosomes (freq: 0.00006), East Asian in 3 of 18862 chromosomes (freq: 0.0002), while the variant was not observed in the African, Latino, Ashkenazi Jewish, Finnish, and South Asian populations. The p.Gly306 residue is conserved across mammals and other organisms, and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the G variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In addition, the yeast-based in vivo assay CHEK2-mediated response to DNA damage showed the variant disturbs CHEK2 DNA damage respond (Roeb 2012). In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.